Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research.

Objective: Based on real-world research, we aimed to evaluate the effectiveness and economy of recombinant human thrombopoietin (rhTPO) and recombinant human interleukin 11 (rhIL-11) in the treatment of cancer therapy induced thrombocytopenia (CTIT). Methods: We retrospectively collected clinical data of patients with CTIT who were treated with rhTPO or rhIL-11 in a single cancer hospital from January 2020 to December 2021. Propensity score matching (PSM) was applied to eliminate confounding factors. The measurements of effectiveness analysis were the platelet compliance rate, days of medication, days of compliance, highest platelet count after medication, platelet count elevation before and after medication, and the lowest platelet count after next-cycle cancer therapy. The economic evaluation was performed according to the results of the effectiveness evaluation. At the same time, patients were stratified according to type of tumor and grade of thrombocytopenia for subgroup analysis. Results: A total of 262 patients were collected and 174 patients were enrolled after PSM, 87 in the rhTPO group and 87 in the rhIL-11 group. In all patients, there were no significant differences in the platelet compliance rate, mean days of medication, median days of compliance, median highest platelet count after medication, and the median platelet count elevation before and after medication between the two groups (p > 0.05), but the median lowest platelet count after next-cycle cancer therapy in the rhTPO group was lower than that in the rhIL-11 group (p = 0.014). The subgroup analysis showed that the rhTPO group had longer mean days of medication than the rhIL-11 group in patients with hematological malignancies (p = 0.042), and a lower median lowest platelet count after next-cycle cancer therapy in patients with grade I/II thrombocytopenia than rhIL-11 group (p = 0.022), with no significant difference in other outcome indicators (p > 0.05). As there was no statistically significant difference in platelet compliance rate between the two groups, the cost-minimization analysis showed that the rhIL-11 group had lower treatment costs than the rhTPO group. Conclusion: RhTPO and rhIL-11 showed similar effectiveness in the treatment of CTIT, but rhIL-11 was more advantageous in economic cost.

Effect of arctiin on glomerular filtration barrier damage in STZ-induced diabetic nephropathy rats.

Diabetic nephropathy (DN) is the major life-threatening complication of diabetes. Abnormal permeability of glomerular basement membrane plays an important role in DN pathogenesis. This study was performed to assess the effect of arctiin, the lignan constituent from Arctium lappa L., on metabolic profile and aggravation of renal lesions in a rat model of streptozotocin (STZ)-induced DN. STZ-induced diabetic rats were treated with arctiin at the dosage of 60 or 40 mg/kg/day via intraperitoneal injection for 8 weeks. Blood glucose and 24-h urinary albumin content were measured, and kidney histopathological changes were monitored. RT-PCR and immunohistochemistry were used to detect the mRNA and protein levels of nephrin, podocin and heparanase (HPSE) in the kidney cortex of rats, respectively. Treatment with arctiin significantly decreased the levels of 24-h urinary albumin, prevented the sclerosis of glomeruli and effectively restored the glomerular filtration barrier damage by up-regulating the expression of nephrin and podocin and down-regulating HPSE level. Our studies suggest that arctiin might be beneficial for DN. The effects of arctiin on attenuating albuminuria and glomerulosclerosis are possibly mediated by regulating the expression of nephrin and podocin and HPSE in STZ-induced diabetic rats.

catena-Poly[[chloridomercury(II)]-µ-1,4-diaza-bicyclo-[2.2.2]octane-κN:N'-[chlorido-mercury(II)]-di-µ-chlorido].

In the title coordination polymer, [Hg(2)Cl(4)(C(6)H(12)N(2))](n), each Hg(II) center within the chain is four-coordinated by one terminal Cl atom, two bridging µ(2)-Cl atoms, and one N-atom donor from a µ(2)-1,4-diaza-bicyclo-[2.2.2]octane (µ(2)-daco) ligand in a distorted tetra-hedral geometry. The daco ligand acts as an end-to-end bridging ligand and bridges adjacent Hg(II) centers, forming a chain running along [001]. Weak C-H⋯Cl hydrogen-bonding inter-actions link the chains into a three-dimensional network. Comparison of the structural differences with previous findings suggests that the space between the two N donors, as well as the skeletal rigidity in N-heterocyclic linear ligands, may play an important role in the construction of such supra-molecular networks.

Diaqua-bis[5-(2-pyrid-yl)tetra-zolato-κN,N]iron(II).

The title complex, [Fe(C(6)H(4)N(5))(2)(H(2)O)(2)], was synthesized by the reaction of ferrous sulfate with 5-(2-pyrid-yl)-2H-tetra-zole (HL). The Fe(II) atom, located on a crystallographic center of inversion, is coordinated by four N-atom donors from two planar trans-related deprotonated L ligands and two O atoms from two axial water mol-ecules in a distorted octa-hedral geometry. The Fe(II) mononuclear units are further connected by inter-molecular O-H⋯N and C-H⋯O hydrogen-bonding inter-actions, forming a three-dimensional framework.

Poly[[diaqua-bis(µ(2)-4,4'-bipyridine)-manganese(II)] bis-[2-(2-carboxy-phenyl-di-sulfanyl)benzoate]].

The title complex, {[Mn(C(10)H(8)N(2))(2)(H(2)O)(2)](C(14)H(9)O(4)S(2))(2)}(n), contains an octa-hedrally coordinated Mn(II) cation and 2-(2-carboxy-phenyl-disulfan-yl)benzoate anions. The Mn(II) center is situated on a crystallographic center of inversion and is coordinated by four 4,4'-bipyridine (4,4'-bipy) ligands and two water mol-ecules. The 4,4'-bipy ligands act as bridging ligands, producing a fishing-net-like two-dimensional framework. In the crystal structure, this positively charged framework is charge balanced by 2-(2-carboxy-phenyl-disulfan-yl)benzoate anions that form a separate anionic two-dimensional framework via inter-molecular O-H⋯O hydrogen bonds and C-H⋯π stacking inter-actions. Additional inter-molecular O-H⋯O hydrogen bonds link the cationic and anionic frameworks to form the three-dimensional crystal structure.

catena-Poly[[dichloridomercury(II)]-micro-1-(2-pyridylmethyl)-1H-benzotriazole]: the effect of different metal centers on the self-assembly of coordination complexes.

To further investigate the relationship between the structures of benzotriazol-1-yl-based pyridyl ligands and their complexes, a new linear one-dimensional Hg(II) coordination polymer, [HgCl(2)(C(12)H(10)N(4))](n), with the 1-(2-pyridylmethyl)-1H-benzotriazole (L) ligand was obtained through the reaction of L with HgCl(2). In this complex, each Hg(II) center within the one-dimensional chain is coordinated by two chloride anions as well as by one pyridine and one benzotriazole N-atom donor of two distinct L ligands in a distorted tetrahedral geometry, forming a linear one-dimensional chain running along the [010] direction. Weak C-H...pi and pi-pi stacking interactions link the one-dimensional motifs to generate an overall two-dimensional network parallel to the (100) plane. Comparison of the structural differences with previous findings suggests that the presence of different metal centers may plays an important role in the construction of such supramolecular frameworks.

Bis{mu-3-[3-(2-pyridyl)pyrazol-1-ylmethyl]pyridine}disilver(I) bis(trifluoromethanesulfonate): effect of counter-anions on the self-assembly of coordination complexes.

As part of a study on the effect of different counter-anions on the self-assembly of coordination complexes, a new dinuclear Ag(I) complex, [Ag(2)(C(14)H(12)N(4))(2)](CF(3)SO(3))(2), with the 3-[3-(2-pyridyl)pyrazol-1-ylmethyl]pyridine (L) ligand was obtained through the reaction of L with AgCF(3)SO(3). In this complex, each Ag(I) center in the centrosymmetric dinuclear complex cation is coordinated by two pyridine and one pyrazole N-atom donor of two inversion-related L ligands in a trigonal planar geometry. This forms a unique box-like cyclic dimer with an intramolecular nonbonding Ag...Ag separation of 6.379 (7) A. Weak Ag...CF(3)SO(3) and C-H...X (X = O and F) hydrogen-bonding interactions, together with pi-pi stacking interactions, link the complex cations along the [001] and [1\overline{1}0] directions, respectively, generating two different one-dimensional chains and then an overall two-dimensional network of the complex running parallel to the (110) plane. Comparison of the structural differences with previous findings suggests that the presence of different counter-anions plays an important role in the construction of such supramolecular frameworks.

Bis[µ-2-(3-pyridylmeth-yl)-2H-benzo-triazole]bis-[nitratosilver(I)].

In the title centrosymmetric binuclear Ag(I) complex, [Ag(2)(NO(3))(2)(C(12)H(10)N(4))(2)], each Ag(I) center is coordinated by one pyridine and one benzotriazole N-donor atom of two inversion-related 2-(3-pyridylmeth-yl)-2H-benzotriazole (L) ligands, and an O atom of a coordinated NO(3) (-) anion in a distorted T-shaped geometry. This forms a unique box-like cyclic dimer with an intra-molecular non-bonding Ag⋯Ag separation of 6.327 (2) Å. Weak inter-molecular Ag⋯O(nitrate) inter-actions [2.728 (4) and 2.646 (3) Å] link the binuclear units, forming a two-dimensional network parallel to (100). Inter-molecular C-H⋯O hydrogen-bonding inter-actions, involving the L ligands and the coordinated NO(3) (-) anions, link the sheets, forming a three-dimensional framework.

[Experimental study on the preventive and treatment function of cortex mori for peripheral nervous lesion at the early stage of diabetes rats].

AIM: To observe the preventive function of cortex mori for peripheral nervous lesion at the early stage in diabetes rats, and probe into the mechanism of that formula. METHODS: Set up the diabetes rat model evoked by alloxan. According to different blood sugar values, randomly divide the rats into normal group, model group, cortex mori(high dosage and low dosage) group and methylcobalamin control group, respectively administer the rats with saline and cortex mori of different dosages by ig (1.875 g/kg, 0.625 g/kg), while 300 microg/kg methylcobalamin for control group, one time each day. Two months after the administration, determine the FBG, body weight, SOD and MDA in blood serum of rats in each group, observe the changes on final product of glycosylation, CGMP and CAMP of sciatic nerve and the synapsin of rats' sciatic nerves. Conduct the pathological observation on area of myelin sheath, extramedullary fiber and the cross section of myelin sheath of sciatic nerves. And observe the changes of ultrafine form of sciatic nerve through transmission electron microscope. In the mean time, determine the MNCV, SNVC and SL, and the tail-flicking test should be undertaken for checking the sensory nerve. RESULTS: Cortex mori can effectively enlarge the area of myelin sheath, extramedullary fiber and the cross section of myelin sheath. CONCLUSION: Cortex mori can obviously ease up the pathological changes of peripheral nerve at the early stage of the diabetes rats, and the overall curative effect is better than that of methylcobalamin.